Atlas Trials

ABL Bio, Inc.

6 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch ABL Bio, Inc.

RecordFirmDate
ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors (NCT07158918)ABL Bio, Inc.2025-08-06
A Study With ABL103 in Subjects With Advanced or Metastatic Solid Tumors (NCT06126666)ABL Bio, Inc.2023-11-07
This is a Study to Evaluate the Safety, Tolerability, PK and PD of IV Administered ABL301 in Healthy Adult Participants (NCT05756920)ABL Bio, Inc.2022-12-31
Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors (NCT05101109)ABL Bio, Inc.2021-10-06
This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors (NCT04762641)ABL Bio, Inc.2021-04-01
This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001 (NCT03292783)ABL Bio, Inc.2017-09-18

Track ABL Bio, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.